01:12:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-29 Kvartalsrapport 2024-Q1
2024-05-27 Ordinarie utdelning SANION 0.00 SEK
2024-05-25 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-25 Årsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-24 Ordinarie utdelning SANION 0.00 SEK
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-08-18 Extra Bolagsstämma 2022
2022-05-27 Ordinarie utdelning SANION 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-09-16 Extra Bolagsstämma 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning SANION 0.00 SEK
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-26 Årsstämma 2021
2021-03-17 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3
2020-10-23 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning SANION 0.00 SEK
2020-05-06 Kvartalsrapport 2020-Q1
2020-05-06 Årsstämma 2020
2020-02-07 Extra Bolagsstämma 2019
2020-02-07 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning SANION 0.00 SEK
2019-05-29 Kvartalsrapport 2019-Q1
2019-05-29 Årsstämma 2019
2019-02-21 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning SANION 0.00 SEK
2018-05-24 Kvartalsrapport 2018-Q1
2018-05-24 Årsstämma 2018
2018-02-21 Bokslutskommuniké 2017
2018-01-19 Extra Bolagsstämma 2018
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning SANION 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-11 Kvartalsrapport 2017-Q1
2017-02-21 Bokslutskommuniké 2016
2016-10-13 Extra Bolagsstämma 2016
2016-05-11 Ordinarie utdelning SANION 0.00 SEK
2016-05-10 Årsstämma 2016
2016-05-10 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-20 Kvartalsrapport 2015-Q3
2015-09-04 Extra Bolagsstämma 2015
2015-08-31 Kvartalsrapport 2015-Q2
2015-05-21 Ordinarie utdelning SANION 0.00 SEK
2015-05-20 Kvartalsrapport 2015-Q1
2015-05-20 Årsstämma 2015
2015-02-20 Bokslutskommuniké 2014
2014-11-21 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2

Beskrivning

LandDanmark
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Saniona är verksamt inom bioteknik. Idag bedrivs forskning och utveckling av läkemedel för behandling av nervsjukdomar samt övriga autoimmuna sjukdomar. Läkemedelsportföljen är bred och innefattar läkemedel som för närvarande befinner sig i olika kliniska faser. En del av arbetet utförs även i samarbete med andra aktörer inom läkemedelsbranschen. Saniona har huvudkontor i Glostrup.
2024-01-10 22:35:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES PURSUANT TO APPLICABLE LAW. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.

On 14 December 2023, the board of directors of Saniona AB (“Saniona” or the “Company”) announced that the board of directors, subject to approval by the extraordinary general meeting in the Company on 16 January 2024, had resolved on an issue of units, consisting of shares and warrants, with preferential rights for the Company’s existing shareholders (the “Rights Issue”). Today, the board of directors of Saniona announces the final terms of the Rights Issue.

Summary

  • Anyone who is registered as a shareholder in Saniona on the record date, 18 January 2024, will receive eight (8) unit rights per one (1) existing share in Saniona. Fifteen (15) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of two (2) shares and one (1) warrant series TO 4. One warrant series TO 4 entitles to subscription of one (1) share in the Company.
  • The Rights Issue entails the issuance of a maximum of 34,201,054 units, corresponding to 68,402,108 shares and 34,201,054 warrants series TO 4.
  • The subscription price in the Rights Issue has been set to SEK 4.12 per unit, corresponding to SEK 2.06 per share. The warrants series TO 4 are issued free of charge.
  • Upon full subscription in the Rights Issue, Saniona will initially receive approximately SEK 140.9 million before issue costs. In the event the warrants series TO 4 are exercised for subscription of new shares, the Company will receive additional proceeds in April 2025.
  • The subscription period in the Rights Issue will run from and including 22 January 2024 up to and including 5 February 2024.
  • The Company intends to use the net proceeds from the Rights Issue to finance repayment of part of outstanding loan, development of the Company’s drug candidate SAN711 and development of other programs in the project portfolio, including SAN2219 and SAN2355, as well as other operational costs.
  • The Rights Issue is subject to approval by the extraordinary general meeting on 16 January 2024.
  • The Rights Issue is covered by subscription undertakings up to approximately 4 per cent and by guarantee commitments up to approximately 56 per cent, corresponding to a total of approximately 60 per cent of the Rights Issue. Among the parties providing the subscription undertakings are senior management and all members of the board of directors, including Thomas Feldthus CEO, with SEK 0.75 million and Jørgen Drejer, chairman of the board of directors, with SEK 0.4 million.

Terms of the Rights Issue

On 14 December 2023, the board of directors resolved, subject to approval by the extraordinary general meeting on 16 January 2024, on the Rights Issue. Anyone who is registered as a shareholder in Saniona on the record date, 18 January 2024, will receive eight (8) unit rights per one (1) existing share in Saniona. Fifteen (15) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of two (2) shares and one (1) warrant series TO 4. One warrant series TO 4 entitles to subscription of one (1) share in the Company.

The Rights Issue entails the issuance of a maximum of 34,201,054 units, corresponding to 68,402,108 shares and 34,201,054 warrants series TO 4.

The subscription price in the Rights Issue has been set to SEK 4.12 per unit, corresponding to SEK 2.06 per share. The subscription price has, in accordance with the principles set out in the Company’s press release on 14 December 2023, been priced at a discount to TERP (theoretical share price after separation of unit rights) of approximately 30 per cent based on the volume-weighted average share price of the Company’s share on Nasdaq Stockholm during the period from and including 4 January 2024 up to and including 10 January 2024. The warrants series TO 4 are issued free of charge. Upon full subscription in the Rights Issue, Saniona will initially receive approximately SEK 140.9 million before issue costs. In the event the warrants series TO 4 are exercised for subscription of new shares, the Company will receive additional proceeds in April 2025.

Subscription of units with or without preferential rights shall be made during the period from and including 22 January 2024 up to and including 5 February 2024. Unit rights that are not exercised during the subscription period become invalid and lose their value. Trading in unit rights takes place on Nasdaq Stockholm during the period from and including 22 January 2024 up to and including 31 January 2024 and trading in BTU (paid subscribed units) during the period from and including 22 January 2024 up until the Rights Issue is registered with the Swedish Companies Registration Office (Sw. Bolagsverket).

One (1) warrant series TO 4 entitles the right to subscribe for one (1) new share in the Company to a subscription price corresponding to seventy (70) per cent of the volume-weighted average price of the Company’s share on Nasdaq Stockholm during the period from and including 28 February 2025 up to and including 13 March 2025, however not less than the share’s quota value. Subscription of shares by exercise of warrants shall be made during the period from and including 18 March 2025 up to and including 1 April 2025.

If not all units are subscribed for by exercise of unit rights, allotment of the remaining units shall be made within the highest amount of the issue: firstly, to those who have subscribed for units by exercise of unit rights (regardless of whether they were shareholders on the record date or not) and who have applied for subscription of units without exercise of unit rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of unit rights that each and every one of those, who have applied for subscription of units without exercise of unit rights, have exercised for subscription of units; secondly, to those who have applied for subscription of units without exercise of unit rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of units the subscriber in total has applied for subscription of units; and thirdly, to those who have provided guarantee commitments with regard to subscription of units, in proportion to such guarantee commitments. To the extent that allotment in any section above cannot be done pro rata, allotment shall be determined by drawing of lots.

Upon full subscription in the Rights Issue, the number of shares in the Company will increase by 68,402,108 shares, from 64,126,978 shares to 132,529,086 shares, and the share capital will increase by SEK 3,420,105.40, from SEK 3,206,348.90 to SEK 6,626,454.30. For existing shareholders who do not participate in the Rights Issue, this means, at full subscription, a dilution effect of approximately 51.6 per cent of the votes and capital in the Company.

If all warrants series TO 4 are fully exercised for subscription of new shares in the Company, the number of shares will increase by an additional 34,201,054, from 132,529,086 shares to a total of 166,730,140 shares, and the share capital will increase by an additional SEK 1,710,052.70, from SEK 6,626,454.30 to SEK 8,336,507. This corresponds to a dilution effect from warrants series TO 4 of an additional maximum of approximately 20.5 per cent. The total dilution effect in the event that both the Rights Issue and the warrants series TO 4 are subscribed for, and exercised, in full, amounts to approximately 61.5 per cent.

Subscription undertakings and guarantee commitments

Saniona has received subscription undertakings from certain existing shareholders and members of the board of directors and senior management, amounting to a total of approximately SEK 5.6 million, corresponding to approximately 4 per cent of the Rights Issue. No compensation will be paid for subscription undertakings. The Company has also entered into agreements with a number of existing and external investors on guarantee commitments of a total of approximately SEK 78.4 million, corresponding to approximately 56 per cent of the Rights Issue. Cash compensation is paid with eleven (11) per cent of the guaranteed amount, corresponding to a total of approximately SEK 8.6 million, or fourteen (14) per cent of the guaranteed amount in the form of newly issued units in the Company, with the same terms and conditions as for units in the Rights Issue, however that the subscription price per unit shall correspond to the volume-weighted average share price of the Company’s share on Nasdaq Stockholm during the subscription period in the Rights Issue (i.e. during the period 22 January – 5 February 2024) multiplied by two (2), however not lower than the subscription price in the Rights Issue.

In total, the Rights Issue is covered by subscription undertakings and guarantee commitments amounting to SEK 84 million, corresponding to approximately 60 per cent of the Rights Issue.

In order to enable issue of units as guarantee compensation to the guarantors who choose to receive guarantee compensation in the form of newly issued units, the board of directors has proposed that the extraordinary general meeting on 16 January 2024 also resolves on authorization for the board of directors to resolve on issue of such units to guarantors.

The guarantors Formue Nord Fokus A/S, Fredrik Lundgren and Wilhelm Risberg have provided guarantee commitments of approximately SEK 78.4 million, which means that they may exceed ten per cent of the votes in Saniona if the Rights Issue is only subscribed up to the level covered by subscription undertakings and guarantee commitments. To the extent the guarantors’ fulfilment of such guarantee entails that the investment must be approved by the Inspectorate of Strategic Products (Sw. Inspektionen för strategiska produkter) in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. lagen (2023:560) om granskning av utländska direktinvesteringar), such part of the guarantee is conditional upon notification that the application of the transaction is left without action or that approval has been obtained from the Inspectorate of Strategic Products.

Lock-up agreements

In connection with the Rights Issue, the board of directors and senior management with shareholdings in Saniona have undertaken towards Vator Securities AB, subject to customary exceptions, not to sell or carry out other transactions with a similar effect as a sale unless, in each individual case, first having obtained written approval from Vator Securities AB. Decisions to give such written consent are resolved upon by Vator Securities AB and an assessment is made in each individual case. Consent may depend on both individual and business reasons. The lock-up undertakings only cover the shares held prior to the Rights Issue and the lock-up period lasts for 180 days after the announcement of the Rights Issue.

Preliminary time plan for the Rights Issue

16 January 2024Extraordinary general meeting
16 January 2024Last day of trading incl. preferential rights
17 January 2024First day of trading incl. preferential rights
18 January 2024Record date for participation in the Rights Issue
18 January 2024Estimated publication of prospectus
22 – 31 January 2024Trading in unit rights on Nasdaq Stockholm
22 January – 5 February 2024Subscription period
22 January 2024 – Until the Rights Issue is registered with the Swedish Companies Registration OfficeTrading in paid subscribed units (Sw. BTU)
Around 7 February 2024Publication of outcome in the Rights Issue

Extraordinary general meeting

The board of directors’ resolution on the Rights Issue is subject to approval by the extraordinary general meeting on 16 January 2024. Notice of the extraordinary general meeting is available on the Company’s website www.saniona.com.

Prospectus

Full terms and conditions for the Rights Issue, as well as other information about the Company will be presented in the prospectus that the Company is expected to publish around 18 January 2024 (the “Prospectus”).

Advisers

Vator Securities AB is financial adviser and Setterwalls Advokatbyrå AB is legal adviser to the Company in connection with the Rights Issue. Vator Securities AB is also issuing agent in connection with the Rights Issue.